ERBB2 and breast carcinoma: In addition, we deciphered the nanomechanicalbinding kinetics and energetics to anti-HER2 VHH-FcK binding to HER2antigen expressed on human breast cancer cells BT-474 and BT-474-TRand compared it with that of Trastuzumab.